Ensign Peak Advisors Inc Sells 1,380 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Ensign Peak Advisors Inc lessened its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 6.4% in the second quarter, Holdings Channel reports. The institutional investor owned 20,107 shares of the medical instruments supplier’s stock after selling 1,380 shares during the period. Ensign Peak Advisors Inc’s holdings in West Pharmaceutical Services were worth $7,221,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. AXA S.A. raised its holdings in West Pharmaceutical Services by 58.8% in the 2nd quarter. AXA S.A. now owns 180,878 shares of the medical instruments supplier’s stock valued at $64,953,000 after buying an additional 66,993 shares during the last quarter. Jupiter Asset Management Ltd. raised its holdings in West Pharmaceutical Services by 17.6% in the 2nd quarter. Jupiter Asset Management Ltd. now owns 19,533 shares of the medical instruments supplier’s stock valued at $7,012,000 after buying an additional 2,926 shares during the last quarter. Park Avenue Securities LLC raised its holdings in West Pharmaceutical Services by 23.2% in the 2nd quarter. Park Avenue Securities LLC now owns 9,914 shares of the medical instruments supplier’s stock valued at $3,560,000 after buying an additional 1,865 shares during the last quarter. O Shaughnessy Asset Management LLC raised its holdings in West Pharmaceutical Services by 10.0% in the 2nd quarter. O Shaughnessy Asset Management LLC now owns 3,651 shares of the medical instruments supplier’s stock valued at $1,311,000 after buying an additional 331 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. raised its holdings in West Pharmaceutical Services by 3.1% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 51,445 shares of the medical instruments supplier’s stock valued at $14,497,000 after buying an additional 1,547 shares during the last quarter. Institutional investors and hedge funds own 92.74% of the company’s stock.

Separately, KeyCorp raised their price target on shares of West Pharmaceutical Services from $350.00 to $475.00 and gave the stock an “overweight” rating in a report on Friday, July 30th.

West Pharmaceutical Services stock opened at $402.25 on Thursday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.39 and a current ratio of 3.13. West Pharmaceutical Services, Inc. has a 52-week low of $253.85 and a 52-week high of $475.35. The firm has a 50 day moving average price of $439.24 and a two-hundred day moving average price of $376.19. The firm has a market cap of $29.76 billion, a price-to-earnings ratio of 58.81, a PEG ratio of 1.96 and a beta of 1.00.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 29th. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.72. The firm had revenue of $723.60 million during the quarter, compared to analyst estimates of $665.55 million. West Pharmaceutical Services had a net margin of 20.58% and a return on equity of 28.58%. As a group, equities research analysts predict that West Pharmaceutical Services, Inc. will post 8.22 EPS for the current fiscal year.

In other news, VP Quintin J. Lai sold 9,672 shares of West Pharmaceutical Services stock in a transaction on Friday, September 10th. The shares were sold at an average price of $460.76, for a total value of $4,456,470.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.66% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers.

Featured Story: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.